Researchers from University of Illinois Chicago have received funding to study a novel diagnostic kit for preeclampsia.
Preeclampsia is pregnancy-related hypertension that can occur at or after 20 weeks of pregnancy. Left untreated, preeclampsia can disrupt fetal growth and lead to preterm birth and stillbirth. In mothers, it can also cause kidney and liver failure and culminate in seizures, coma and death. Delivery of the baby is the most effective treatment, and blood pressure usually returns to normal once this takes place.
Dr. Irina Buhimschi and Dr. Gelila Goba.
Products and exhibitors around diagnostic tests
Exhibitors and products related to this topic can be found in the database of MEDICA 2021:
In communities with limited access to health care, the diagnosis of preeclampsia relies primarily on a combination of blood pressure and urine protein tests. However, there are no definitive means for diagnosing preeclampsia, said Dr. Gelila Goba, associate professor of obstetrics and gynecology at the UIC College of Medicine. Goba is co-principal investigator of the study, along with Dr. Irina Buhimschi, also an OBGYN professor at UIC.
Buhimschi is one of the inventors of the Congo Red Dot test, a urine test for preeclampsia. Co-developed by researchers at Yale University, the test has been licensed for commercial development.
The study will take place in Ethiopia and Uganda over the next nine months. If successful, it could lead to clinical use in these countries and serve as a model for adoption across Africa and the developing world. In developing countries, the challenge in diagnosing preeclampsia is greater due to lack of equipment and limited access to prenatal care.
"Our study aims to introduce a new technology simultaneously in Ethiopia and Uganda with a goal of developing clinical protocols and understanding the potential barriers to integration of novel preeclampsia diagnostics," Goba said.
"We believe every pregnancy should be supported with access to tools that promote healthy moms and babies," Buhimschi said. "Testing for pre-eclampsia is an important preventive intervention and we aim to help ensure every health care provider in the world has access to testing and understands how best to use it no matter the continent or country where they live."
The study received $496,472 Canadian dollars from Grand Challenges Canada, a Canadian nonprofit organization funded by the Government of Canada and other partners to support global health, humanitarian and Indigenous innovators in low- and middle-income countries and Canada.
Several academic institutions in Africa will be collaborating with UIC, including Makerere University in Uganda and Jimma University in Ethiopia. The Ethiopian Society of Obstetricians & Gynecologists will coordinate activities in Ethiopia. Gynuity Health Projects, a nonprofit research organization based in New York City with extensive experience in international clinical trials will provide technical assistance.
MEDICA-tradefair.com; Source: University of Illinois Chicago